TY - JOUR
T1 - Delivery of neutrophil membrane encapsulated non-steroidal anti-inflammatory drugs by degradable biopolymer microneedle patch for rheumatoid arthritis therapy
AU - Lin, Yixuan
AU - Chen, Yang
AU - Deng, Ronghui
AU - Qin, Hao
AU - Li, Nan
AU - Qin, Yuting
AU - Chen, Hanqing
AU - Wei, Yaohua
AU - Wang, Zeming
AU - Sun, Qing
AU - Qiu, Wenyi
AU - Shi, Jian
AU - Chen, Long
AU - Wang, Yuguang
AU - Nie, Guangjun
AU - Zhao, Ruifang
N1 - Funding Information:
This work was supported by grants from the National Basic Research Plan of China ( 2018YFE0205300 to RZ), the National Natural Science Foundation of China ( 32171370 to HC, 91942304 to GN, and 11621505 to GN), the Key Area Research and Development Program of Guangdong Province ( 2020B0101020004 to RZ), the National Basic Science Center Project ( T2288102 to GN).
Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/4
Y1 - 2023/4
N2 - Rheumatoid arthritis (RA) is a common chronic autoimmune disease and eventually ends in severe disability and death. RA has no cure, but there are some treatments for decreasing the severity of various symptoms. For example, pain management of RA by non-steroidal anti-inflammatory drugs (NSAIDs), neutralization of the inflammatory cytokines (or block their functions) of RA by specific biologics. However, the clinical benefit is limited due to their low permeability and poor bioavailability. Meanwhile, the system toxicity for long-term use of NSAIDs is another focal issue. Herein, degradable biopolymer microneedle patch was designed and synthesized. In this dual drug delivery patch, NSAIDs were encapsulated by polymeric nanoparticles, which were coated by the neutrophil membrane, followed by loaded into the microneedle patch for local transdermal delivery. When applied to the murine models, the microneedle patch gradually dissolves and releases the contained nanoparticles. Coating of neutrophil membrane provides the nanosized NSAIDs with the capability of cytokine binding and inflammatory joint tropism. Based on inflammatory microenvironment regulation by cytokine absorption and cyclooxygenase-2 inhibition, the microneedle shows a significant local anti-inflammatory therapeutic effect on mouse model of collagen-induced arthritis and rat model of adjuvant-induced arthritis. Further development based on this advanced strategy may provide additional therapeutic options for RA treatment.
AB - Rheumatoid arthritis (RA) is a common chronic autoimmune disease and eventually ends in severe disability and death. RA has no cure, but there are some treatments for decreasing the severity of various symptoms. For example, pain management of RA by non-steroidal anti-inflammatory drugs (NSAIDs), neutralization of the inflammatory cytokines (or block their functions) of RA by specific biologics. However, the clinical benefit is limited due to their low permeability and poor bioavailability. Meanwhile, the system toxicity for long-term use of NSAIDs is another focal issue. Herein, degradable biopolymer microneedle patch was designed and synthesized. In this dual drug delivery patch, NSAIDs were encapsulated by polymeric nanoparticles, which were coated by the neutrophil membrane, followed by loaded into the microneedle patch for local transdermal delivery. When applied to the murine models, the microneedle patch gradually dissolves and releases the contained nanoparticles. Coating of neutrophil membrane provides the nanosized NSAIDs with the capability of cytokine binding and inflammatory joint tropism. Based on inflammatory microenvironment regulation by cytokine absorption and cyclooxygenase-2 inhibition, the microneedle shows a significant local anti-inflammatory therapeutic effect on mouse model of collagen-induced arthritis and rat model of adjuvant-induced arthritis. Further development based on this advanced strategy may provide additional therapeutic options for RA treatment.
KW - Immunomodulation
KW - Microneedle patch
KW - NSAIDs
KW - Neutrophil membrane
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85148699105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148699105&partnerID=8YFLogxK
U2 - 10.1016/j.nantod.2023.101791
DO - 10.1016/j.nantod.2023.101791
M3 - Article
AN - SCOPUS:85148699105
SN - 1748-0132
VL - 49
JO - Nano Today
JF - Nano Today
M1 - 101791
ER -